BCAL Diagnostics Limited (AU:BDX) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
BCAL Diagnostics Limited’s Director, Jayne Shaw, has increased her stake in the company by acquiring 2,000,000 ordinary shares and 2,000,000 options, reflecting a strategic move approved at the recent Annual General Meeting. This acquisition, which involves no cash consideration, could indicate confidence in the company’s future prospects. Investors may want to watch how this development impacts BCAL Diagnostics’ performance in the stock market.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.